Use of Sitagliptin to Decrease Microalbuminuria

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 142 participants.

Also called NCT02048904

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 142 participants (enrolled count) (from the registry)
Sponsor
University of Missouri-Columbia (from the registry)
Registry
  • NCT NCT02048904
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02048904. Randomized; double masking; primary purpose treatment. Start 2014-01 (registry gives no type); primary completion 2016-01 (actual). Results posted on 2017-08-10.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Use of Sitagliptin to Decrease Microalbuminuria
Condition
Microalbuminuria
Intervention (Drug)
Sitagliptin
Intervention (Drug)
Placebo
Lead sponsor
University of Missouri-Columbia (class: other)

Record details

Record id
cardio:ct-nct02048904
Content hash
c455362e8bfa5e9c5489e463bc77fae9554355578d07e2c86928d0ffc0340724